Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990;336(8708):156–8.
Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Brit J Clin Pharmacol. 1988;26(1):1–5.
Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf. 2000;22(6):415–23.
Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539–46.
Public Law 110-85: Food and Drug Administration Amendments Act of 2007. 2007.
Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011;62:1–10.
Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.
Norén GN, Bate A, Hopstadius J, Star K, Edwards IR. Temporal pattern discovery for trends and transient effects: its application to patient records. In: ACM SIGKDD international conference on knowledge discovery and data mining, KDD ‘08. Las Vegas: ACM; 2008. p. 963–71.
Suissa S. The case–time–control design. Epidemiology. 1995;6(3):248–53.
Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15.
Norén GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: results on real-world data. Pharmacoepidemiol Drug Saf. 2012;21(6):673–5.
Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670–2.
Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013 (in this supplement issue). doi:10.1007/s40264-013-0097-8.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013 (in this supplement issue). doi:10.1007/s40264-013-0101-3.
Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:5.
Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143(11):1165–73.
Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.
Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81.
Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670–2. doi:10.1002/pds.3259.
Tisdale J, Miller D. Drug-induced diseases: prevention, detection, and management. 2nd ed. USA: American Society of Health-System Pharmacists; 2010.
Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126(2):356–8.
Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839–43.
Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183(3):E173–9.
Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576–83.
Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56.
Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.